The D409H variant in GBA1 : Challenges in predicting the Gaucher phenotype in the newborn screening era
American Journal of Medical Genetics Part A · 2023
DOI: 10.1002/ajmg.a.63202 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2023. Verfasst von Adenrele M Gleason und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Glucosylceramidase, Gaucher Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Gaucher disease (GD) is an autosomal recessive disorder resulting from glucocerebrosidase deficiency due to pathologic variants in GBA1 . While clinically heterogeneous, GD encompasses three types, non‐neuronopathic (GD1), acute neuronopathic (GD2), and chronic neuronopathic (GD3). Newborn screening (NBS), which has made remarkable inroads in detecting certain diseases before detrimental health consequences and fatality ensues, is now being piloted for GD in several states and countries. Early on, clinical features of GD2 can overlap with GD3; hence, predicting outcome is challenging. As NBS for GD becomes more available, the increased detection of GD in neonates is inevitable. As a result, health care providers and families will be faced with uncertainty with respect to clinical management. Since more severe GBA1 variants are generally associated with neuronopathic GD, there has been an increased dependence on genotypic information. We present an infant detected by NBS with genotype D409H(p.Asp448His)/Rec Nci I (p.Leu483Pro; p.Ala495Pro;p.Val499=). To assist in genetic counseling, we performed a retrospective review of other patients in our cohort carrying D409H and reviewed the literature. The study illustrates the challenges faced in counseling for infants with neuronopathic GD, even with known GBA1 variants, and the tough management decisions that can ensue from detection in newborns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Medical Genetics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, USA.
ORCID-Profile: Ellen Sidransky
Zitieren
APA
Gleason, A. M., D'Souza, A., Ryan, E., Grochowsky, A. R., Carter, C. R., Goker-Alpan, O., Lopez, G., Tayebi, N., & Sidransky, E. (2023). The D409H variant in GBA1 : Challenges in predicting the Gaucher phenotype in the newborn screening era. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63202
Vancouver
Gleason AM, D'Souza A, Ryan E, Grochowsky AR, Carter CR, Goker-Alpan O, et al. The D409H variant in GBA1 : Challenges in predicting the Gaucher phenotype in the newborn screening era. American Journal of Medical Genetics Part A. 2023. doi:10.1002/ajmg.a.63202
BibTeX
@article{Gleason2023,
author = {Gleason, Adenrele M and D'Souza, Andrea and Ryan, Emory and Grochowsky, Angela R and Carter, Camille R and Goker-Alpan, Ozlem and Lopez, Grisel and Tayebi, Nahid and Sidransky, Ellen},
title = {The D409H variant in GBA1 : Challenges in predicting the Gaucher phenotype in the newborn screening era},
journal = {American Journal of Medical Genetics Part A},
year = {2023},
doi = {10.1002/ajmg.a.63202}
}
EUVIMED